Thirteen-week oral toxicity study of difluoromethylornithine in combination with tamoxifen citrate in female dogs

被引:5
作者
Brown, AP
Morrissey, RL
Crowell, JA
Levine, BS
机构
[1] Univ Illinois, Dept Pharmacol, Toxicol Res Lab, Chicago, IL 60612 USA
[2] Pathol Assoc Int, Chicago, IL USA
[3] NCI, Div Canc Prevent & Control, NIH, Rockville, MD USA
关键词
tamoxifen; difluoromethylornithine; dogs; reproductive system toxicity; GI toxicity;
D O I
10.1007/s002800050927
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Cancer chemoprevention is the use of pharmacologic or natural agents to inhibit the development of cancer. Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme in the biosynthesis of polyamines. DFMO has demonstrated chemopreventive efficacy in animal models of tumorigenesis. Tamoxifen (TAM), a nonsteroidal antiestrogen, is approved for use in the treatment of estrogen receptor-positive breast carcinoma and has demonstrated efficacy in chemoprevention of breast cancer in women at high risk for the disease. The administration of TAM with DFMO is being considered for development by the National Cancer Institute as a potential drug regimen for the chemoprevention of breast carcinoma. Methods: The toxicity of DFMO in combination with TAM was evaluated in female Beagle dogs following 13 weeks of daily oral administration by capsule. Dose levels in milligrams per kilogram body weight per day were: 0 (vehicle control), 100 DFMO, 0.1 TAM, 1.0 TAM, 0.1 TAM + 100 DFMO and 1.0 TAM + 100 DFMO. Results: No mortalities occurred. Diarrhea was produced by TAM and vaginal discharge, due to reproductive tract lesions, was produced by both DFMO and TAM, either alone or in combination. DFMO decreased reticulocyte counts and TAM increased counts of mature neutrophils. DFMO alone resulted in lesions to the intestines and ovaries, and cornified epithelium of vagina and cervix. TAM produced cornified epithelium of vagina and cervix, and numerous lesions in the ovaries, fallopian tube, uterus, cervix and vagina which were likely due to an estrogen agonist effect. Coadministration of DFMO increased the incidence and/or severity of these reproductive tract lesions. Each compound alone produced ovarian atrophy, and antral follicles and corpora lutea were completely absent in the 1.0 TAM + 100 DFMO group. Conclusions: Coadministration of DFMO and TAM resulted in additive toxicity involving the female reproductive system.
引用
收藏
页码:479 / 488
页数:10
相关论文
共 13 条
  • [1] Thirteen-week oral toxicity study of difluoromethylornithine in combination with tamoxifen citrate in female dogs
    Alan P. Brown
    Robert L. Morrissey
    James A. Crowell
    Barry S. Levine
    Cancer Chemotherapy and Pharmacology, 1999, 43 : 479 - 488
  • [2] Difluoromethylornithine in combination with tamoxifen in female rats: 13-week oral toxicity study
    Brown, AP
    Morrissey, RL
    Crowell, JA
    Levine, BS
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (06) : 475 - 483
  • [3] Difluoromethylornithine in combination with tamoxifen in female rats: 13-week oral toxicity study
    Alan P. Brown
    Robert L. Morrissey
    James A. Crowell
    Barry S. Levine
    Cancer Chemotherapy and Pharmacology, 1999, 44 : 475 - 483
  • [4] Subchronic toxicity and toxicogenomic evaluation of tamoxifen citrate plus bexarotene in female rats
    Horn, Thomas L.
    Torres, Karen E. O.
    Naylor, Jennifer M.
    Cwik, Michael J.
    Detrisac, Carol J.
    Kapetanovic, Izet M.
    Lubet, Ronald A.
    Crowell, James A.
    McCormick, David L.
    TOXICOLOGICAL SCIENCES, 2007, 99 (02) : 612 - 627
  • [5] Toxicokinetic assessment of methylphenidate (Ritalin®) in a 13-week oral toxicity study in dogs
    Bakhtiar, R
    Ramos, L
    Tse, FLS
    BIOMEDICAL CHROMATOGRAPHY, 2004, 18 (01) : 45 - 50
  • [6] Collaborative work on evaluation of ovarian toxicity 3) Effects of 2-or 4-week repeated-dose toxicity and fertility studies with tamoxifen in female rats
    Tsujioka, Shigeharu
    Ban, Yoshiki
    Wise, L. David
    Tsuchiya, Takayuki
    Sato, Takahiro
    Matsue, Kenta
    Ikeda, Takanori
    Sasaki, Minoru
    Nishikibe, Masaru
    JOURNAL OF TOXICOLOGICAL SCIENCES, 2009, 34 : SP43 - SP51
  • [7] Subacute toxicity and toxicokinetics of CJ-10882, a type IV phosphodiesterase inhibitor, after 4-week repeated oral administration in dogs
    Han, J
    Shin, HC
    Kim, JC
    Kim, B
    FOOD AND CHEMICAL TOXICOLOGY, 2004, 42 (03) : 373 - 380
  • [8] 4-Week repeated intravenous dose toxicity study of a new camptothecin anticancer agent CKD-602 in dogs
    Kim, JC
    Shin, DH
    Park, SH
    Park, SC
    Kim, YB
    Kim, HC
    Cha, SW
    Cho, KH
    Kang, BH
    Chung, MK
    FOOD AND CHEMICAL TOXICOLOGY, 2005, 43 (05) : 699 - 706
  • [9] Tamoxifen:: 28-day oral toxicity study in the rat based on the Enhanced OECD Test Guideline 407 to detect endocrine effects
    Kennel, P
    Pallen, C
    Barale-Thomas, E
    Espuña, G
    Bars, R
    ARCHIVES OF TOXICOLOGY, 2003, 77 (09) : 487 - 499
  • [10] Tamoxifen: 28-day oral toxicity study in the rat based on the Enhanced OECD Test Guideline 407 to detect endocrine effects
    Philippe Kennel
    Catherine Pallen
    Erio Barale-Thomas
    Gemma Espuña
    Remi Bars
    Archives of Toxicology, 2003, 77 : 487 - 499